Vision Loss & GLP-1 Medications
Studies have linked GLP-1 medications including Ozempic, Wegovy, and Mounjaro to an increased risk of NAION — a serious condition that causes sudden, often permanent vision loss. Federal litigation is now underway.
What Is NAION
NAION (non-arteritic anterior ischemic optic neuropathy) occurs when blood flow to the optic nerve is suddenly disrupted, causing damage to the nerve fibers that carry visual information from the eye to the brain. It is the most common cause of acute optic nerve damage in adults over 50.
Patients with NAION typically experience sudden, painless vision loss in one eye — often noticed upon waking. The vision loss can range from mild blurring or dimming to complete blindness in the affected eye. In some cases, the other eye may also be affected over time. There is currently no proven treatment to restore vision lost to NAION.
NAION can profoundly affect daily life, impacting the ability to drive, read, work, and perform routine tasks. The sudden and often permanent nature of the vision loss makes it a devastating diagnosis.
Link Between GLP-1 Drugs and Vision Loss
Research published in peer-reviewed medical journals has identified a significant association between GLP-1 receptor agonist medications — particularly semaglutide (Ozempic, Wegovy, Rybelsus) — and an increased risk of developing NAION. Studies have shown that patients using these medications may face a substantially higher risk of NAION compared to the general population.
While the exact mechanism is still being studied, researchers believe GLP-1 medications may affect blood flow to the optic nerve, potentially through changes in blood pressure, vascular function, or rapid weight loss. The risk appears to be present across patients using GLP-1 drugs for both diabetes management and weight loss.
Lawsuits allege that the manufacturers of these medications knew or should have known about the vision loss risk and failed to adequately warn patients and prescribing physicians, depriving them of the ability to make informed decisions about their treatment.
Current Litigation Status
Vision loss claims against GLP-1 drug manufacturers have been consolidated in MDL 3163 (In Re: Glucagon-Like Peptide-1 Receptor Agonists [GLP-1 RAs] Vision Injury Products Liability Litigation) in the Eastern District of Pennsylvania.
Approximately 54 cases are currently pending, with new cases continuing to be filed. This MDL is separate from the larger gastrointestinal injury litigation (MDL 3094), reflecting the distinct nature of the vision loss injuries.
The litigation is in its early stages. As scientific evidence continues to emerge and more affected patients come forward, the number of cases is expected to grow. No settlements have been reached yet, and bellwether trial scheduling is still being determined.
Do You Qualify?
You may be eligible to file a GLP-1 vision loss claim if the following apply:
Used a GLP-1 Medication
You were prescribed and used Ozempic, Wegovy, Rybelsus, Mounjaro, or another GLP-1 receptor agonist medication.
Diagnosed with NAION
You were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) or experienced sudden, unexplained vision loss after starting the medication.
Ophthalmologist Confirmation
Your vision loss was evaluated and documented by an ophthalmologist or neuro-ophthalmologist, providing medical evidence of NAION or optic nerve damage.
Not Already Represented
You are not currently represented by another attorney for this specific claim.
Frequently Asked Questions
What is NAION?
NAION (non-arteritic anterior ischemic optic neuropathy) is a condition caused by reduced blood flow to the optic nerve, resulting in sudden, painless vision loss in one eye. It is the most common cause of acute optic nerve damage in adults over 50. Vision loss from NAION is often permanent and can range from mild blurring to complete blindness in the affected eye.
How are GLP-1 medications linked to vision loss?
Studies have found that patients using semaglutide-based medications (Ozempic, Wegovy, Rybelsus) have a significantly elevated risk of developing NAION compared to the general population. Researchers believe the drugs may affect blood flow to the optic nerve, though the exact mechanism is still being studied. The FDA and medical community have flagged this association, and litigation is now underway.
Which GLP-1 drugs are linked to NAION?
The strongest evidence currently links semaglutide-based medications — Ozempic, Wegovy, and Rybelsus — to NAION. However, other GLP-1 receptor agonists including Mounjaro, Saxenda, and Trulicity may also carry similar risks. The litigation is still in its early stages, and the scope of included medications may expand as more evidence emerges.
What is the status of the vision loss litigation?
Vision loss cases are consolidated in MDL 3163 in the Eastern District of Pennsylvania, with approximately 54 pending cases. This litigation is in its early stages and is separate from the larger gastrointestinal injury MDL. As more cases are filed and evidence is gathered, the litigation is expected to grow.
What does it cost to file a claim?
There is no cost to you. Attorneys handling GLP-1 vision loss cases work on a contingency fee basis, meaning they only get paid if you receive compensation. NuLegal's initial case review is completely free with no obligation.
Don't Wait
Statutes of limitations may limit how long you have to file. Get a free, no-obligation case review today to find out if you qualify for compensation.
Free Case ReviewAdvertisement